Premium
Analysis of the REL , BCL11A , and MYCN proto‐oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia
Author(s) -
Deambrogi Clara,
De Paoli Lorenzo,
Fangazio Marco,
Cresta Stefania,
Rasi Silvia,
Spina Valeria,
Gattei Valter,
Gaidano Gianluca,
Rossi Davide
Publication year - 2010
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21742
Subject(s) - chronic lymphocytic leukemia , amplicon , leukemia , medicine , oncology , cancer research , hematology , biology , genetics , gene , polymerase chain reaction
International audienceThe exact prevalence of gains of proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia (CLL) is currently unknown. We analysed the REL, BCL11A, and MYCN loci by FISH in a consecutive series of 176 newly diagnosed CLL. REL gain occurred in 3.4% cases, BCL11A gain in 2.8%, and MYCN gain in 2.3%. CLL harbouring MYCN gain showed an increased risk of death (HR:5.35; p=.006). By multivariate analysis, MYCN gain was an independent predictor of survival in CLL (HR:4.79; p=.017). Our observations indicate that: i) gains of REL, BCL11A and MYCN occur at a low frequency at CLL diagnosis; and ii) MYCN gain has potential prognostic relevance in CLL
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom